



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 1 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1800/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 4633 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

U.S. PATENT DOCUMENTS

Ex'r Initial	Ref. No.	Document No.	Date	Name	Class	SubClass	Filed
NC	A1	5,032,510	July 16, 1991	Kovacevic et al.			
	A2	RE 33,653	July 30, 1991	Mark et al.			
	A3	5,128,319	July 7, 1992	Arlinghaus			
	A4	5,256,767	October 26, 1993	Salk et al.			
	A5	5,304,472	April 19, 1994	Bass et al.			
	A6	5,364,773	November 15, 1994	Paoletti et al.			
	A7	5,419,900	May 30, 1995	Lane et al.			
	A8	5,503,833	April 2, 1996	Redmond et al.			
	A9	5,550,280	August 27, 1996	Dao-Cong et al.			
	A10	5,637,677	June 10, 1997	Greene et al.			
	A11	5,665,569	September 9, 1997	Ohno			
	A12	5,665,720	September 9, 1997	Young et al.			
	A13	5,670,152	September 23, 1997	Weiner et al.			
	A14	5,683,864	November 4, 1997	Houghton et al.			
	A15	5,686,078	November 11, 1997	Becker et al.			
	A16	5,693,755	December 2, 1997	Buonagurio et al.			
	A17	5,712,088	January 27, 1998	Houghton et al.			

Examiner: 

Date Considered: 03/21/06


EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - Reference were not considered.

COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 2 of 24



In re: Application of Barnett et al.

Serial No.: 09/899,575

Filed: July 5, 2001

Examiner: Unassigned

Art Unit: 1633 1648

Confirmation No.: 1709

RECEIVED
JUN 11 2003
TECH CENTER 1600/000

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	A18	5,714,596	February 3, 1998	Houghton et al.			
	A19	5,728,520	March 17, 1998	Weiner et al.			
	A20	5,741,492	April 21, 1998	Hurwitz et al.			
	A21	5,750,373	May 12, 1998	Garrard et al.			
	A22	5,766,845	June 16, 1998	Weiner et al.			
	A23	5,817,637	October 6, 1998	Weiner et al.			
	A24	5,837,242	November 17, 1998	Holliger et al.			
	A25	5,837,818	November 17, 1998	Buonagurio et al.			
	A26	5,840,313	Nov. 24, 1998	Vahine et al.			
	A27	5,846,546	December 8, 1998	Hurwitz et al.			
	A28	5,853,736	December 29, 1998	Becker et al.			
	A29	5,858,675	January 12, 1999	Hillman et al.			
	A30	5,866,320	February 2, 1999	Rovinski et al.			
	A31	5,871,747	February 16, 1999	Gengoux-Sedlik et al.			
	A32	5,876,731	March 2, 1999	Sia et al.			
	A33	5,879,907	March 9, 1999	Aberg, et al.			
	A34	5,879,925	March 9, 1999	Rovinski, et al.			
	A35	5,889,176	March 30, 1999	Rovinski et al.			
	A36	5,932,445	August 3, 1999	Lal et al.			

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 3 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit-1633-1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	A37	5,951,975	September 14, 1999	Falo Jr., et al.			
	A38	5,955,342	September 21, 1999	Rovinski et al.			
	A39	5,965,726	October 12, 1999	Pavliakis et al.			
	A40	5,972,596	October 26, 1999	Pavliakis et al.			
	A41	6,001,977	December 14, 1999	Chang et al.			
	A42	6,004,763	December 21, 1999	Gengoux et al.			
	A43	6,025,125	February 15, 2000	Rovinski et al.			
	A44	6,060,273	May 9, 2000	Dirks et al.			
	A45	6,060,587	May 9, 2000	Weiner et al.			
	A46	6,063,384	May 16, 2000	Morrow et al.			
	A47	6,074,636	June 13, 2000	Nichols			
	A48	6,080,408	June 27, 2000	Rovinski et al.			
	A49	6,087,486	July 11, 2000	Weiner et al.			
	A50	6,093,800	July 25, 2000	Reiter et al.			
	A51	6,096,505	August 1, 2000	Selby et al.			
	A52	6,099,847	August 8, 2000	Tobin et al.			
	A53	6,114,148	September 5, 2000	Seed et al.			
	A54	6,132,973	October 17, 2000	Lal et al.			
↓	A55	6,139,833	October 31, 2000	Burgess et al.			

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

848137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 4 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1800/2300

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1633

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	A56	6,140,059	October 31, 2000	Schawaller			
	A57	6,146,635	November 14, 2000	Cano et al.			
	A58	6,172,201	January 9, 2001	Weiner et al.			
	A59	6,174,666	January 16, 2001	Pavliakis et al.			
	A60	6,214,804	April 10, 2001	Felgner et al.			
	A61	6,291,157	September 18, 2001	Rovinski et al.			
	A62	6,291,664	September 18, 2001	Pavliakis et al.			
	A63	6,316,253	November 13, 2001	Innis et al.			
	A64	6,331,404	December 18, 2001	Berman et al.			

FOREIGN PATENT DOCUMENTS

Ex'r Initial	Ref. No.	Document No.	Published	Country	Class	SubClass	Translation	
							YES	NO
NC	B1	WO 86/03224	June 5, 1986	PCT				
	B2	WO 87/02775	May 7, 1987	PCT				
	B3	WO 88/00471	January 28, 1988	PCT				
	B4	WO 88/10300	December 29, 1988	PCT				
	B5	WO 89/01940	March 9, 1989	PCT				
	B6	WO 89/02277	March 23, 1989	PCT				
	B7	WO 89/02922	April 6, 1989	PCT				

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - references were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 5 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~4633~~ - 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B8	WO 89/03222	April 20, 1989	PCT				
	B9	WO 90/02568	March 22, 1990	PCT				
	B10	WO 90/03984	April 19, 1990	PCT				
	B11	WO 90/10438	September 20, 1990	PCT				
	B12	WO 90/11092	October 4, 1990	PCT				
	B13	WO 90/11359	October 4, 1990	PCT				
	B14	WO 90/12094	October 18, 1990	PCT				
	B15	WO 90/15141	December 13, 1990	PCT				
	B16	WO 91/04273	April 4, 1991	PCT				
	B17	WO 91/06319	May 16, 1991	PCT				
	B18	WO 91/07425	May 30, 1991	PCT				
	B19	WO 91/07510	May 30, 1991	PCT				
	B20	WO 91/13360	September 5, 1991	PCT				
	B21	WO 91/13906	September 19, 1991	PCT				
	B22	WO 91/15238	October 17, 1991	PCT				
	B23	WO 91/15512	October 17, 1991	PCT				
	B24	WO 91/16926	November 14, 1991	PCT				
	B25	WO 91/18928	December 12, 1991	PCT				
↓	B26	WO 91/19803	December 26, 1991	PCT				

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 6 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 4633-1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B27	WO 92/03475	March 5, 1992	PCT				
	B28	WO 92/04046	March 19, 1992	PCT				
	B29	WO 92/05799	April 16, 1992	PCT				
	B30	WO 93/02102	February 4, 1993	PCT				
	B31	WO 93/04090	March 4, 1993	PCT				
	B32	WO 93/08836	May 13, 1993	PCT				
	B33	WO 93/14789	August 5, 1993	PCT				
	B34	WO 93/20212	October 14, 1993	PCT				
	B35	WO 93/21346	October 28, 1993	PCT				
	B36	WO 93/23569	November 25, 1993	PCT				
	B37	WO 94/04574	March 3, 1994	PCT				
	B38	WO 94/07922	April 14, 1994	PCT				
	B39	WO 94/11523	May 26, 1994	PCT				
	B40	WO 94/13804	June 23, 1994	PCT				
	B41	WO 94/15621	July 21, 1994	PCT				
	B42	WO 94/16060	July 21, 1994	PCT				
	B43	WO 94/16737	August 4, 1994	PCT				
	B44	WO 94/18221	August 18, 1994	PCT				
	B45	WO 94/20141	September 15, 1994	PCT				

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 7 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~1633~~ 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B46	WO 94/20640	September 15, 1994	PCT				
	B47	WO 94/22477	October 13, 1994	PCT				
	B48	WO 94/26293	November 24, 1994	PCT				
	B49	WO 94/29339	December 22, 1994	PCT				
	B50	WO 95/03407	February 2, 1995	PCT				
	B51	WO 95/04818	February 16, 1995	PCT				
	B52	WO 95/11317	April 27, 1995	PCT				
	B53	WO 95/11701	May 4, 1995	PCT				
	B54	WO 95/24485	September 14, 1995	PCT				
	B55	WO 95/25124	September 21, 1995	PCT				
	B56	WO 95/27505	October 19, 1995	PCT				
	B57	WO 95/29700	November 9, 1995	PCT				
	B58	WO 95/33206	December 7, 1995	PCT				
	B59	WO 95/33835	December 14, 1995	PCT				
	B60	WO 96/02273	February 1, 1996	PCT				
	B61	WO 96/02557	February 1, 1996	PCT				
	B62	WO 96/04382	February 15, 1996	PCT				
	B63	WO 96/09066	March 28, 1996	PCT				
	B64	WO 96/09378	March 28, 1996	PCT				

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 8 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2300

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1633 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B65	WO 96/16178	May 30, 1996	PCT				
	B68	WO 96/20732	July 11, 1996	PCT				
	B67	WO 96/23509	August 8, 1996	PCT				
	B68	WO 96/25177	August 22, 1996	PCT				
	B69	WO 96/30523	October 3, 1996	PCT				
	B70	WO 96/40290	December 19, 1996	PCT				
	B71	WO 97/03198	January 30, 1997	PCT				
	B72	WO 97/11605	April 3, 1997	PCT				
	B73	WO 97/26009	July 24, 1997	PCT				
	B74	WO 98/08539	March 5, 1998	PCT				
	B75	WO 98/34640	August 13, 1998	PCT				
	B76	WO 98/41536	September 24, 1998	PCT				
	B77	WO 98/41645	September 24, 1998	PCT				
	B78	WO 98/43182	October 1, 1998	PCT				
	B79	WO 98/48843	November 5, 1998	PCT				
	B80	WO 98/59074	December 30, 1998	PCT				
	B81	WO 99/02694	January 21, 1999	PCT				
	B82	WO 99/06599	February 11, 1999	PCT				
	B83	WO 99/09412	February 25, 1999	PCT				

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - Reference were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 9 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1635-1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B84	WO 99/12416	March 18, 1999	PCT				
	B85	WO 99/13864	March 25, 1999	PCT				
	B86	WO 99/16883	April 8, 1999	PCT				
	B87	WO 99/33346	July 8, 1999	PCT				
	B88	WO 99/41398	August 19, 1999	PCT				
	B89	WO 99/52463	October 21, 1999	PCT				
	B90	WO 99/53960	October 28, 1999	PCT				
	B91	WO 99/67395	December 29, 1999	PCT				
	B92	WO 00/08043	February 17, 2000	PCT				
	B93	WO 00/18929	April 6, 2000	PCT				
	B94	WO 00/21556	April 20, 2000	PCT				
	B95	WO 00/39302	July 6, 2000	PCT				
	B96	WO 00/39303	July 6, 2000	PCT				
	B97	WO 00/39304	July 6, 2000	PCT				
	B98	WO 00/44926	August 3, 2000	PCT				
	B99	WO 00/65076	November 2, 2000	PCT				
	B100	WO 00/66179	November 9, 2000	PCT				
	B101	WO 00/67761	November 16, 2000	PCT				
	B102	WO 00/67787	November 16, 2000	PCT				

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 10 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1633 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B103	WO 00/71561	November 30, 2000	PCT					
	B104	WO 01/02607	January 11, 2001	PCT					
	B105	WO 01/12223	February 22, 2001	PCT					
	B106	WO 01/16342	March 8, 2001	PCT					
	B107	WO 01/19958	March 22, 2001	PCT					
	B108	WO 01/21270	March 29, 2001	PCT					
	B109	WO 01/26681	April 19, 2001	PCT					
	B110	WO 01/29225	April 26, 2001	PCT					
	B111	WO 01/36814	May 25, 2001	PCT					
	B112	WO 01/42308	June 14, 2001	PCT					
	B113	WO 01/43693	June 21, 2001	PCT					
	B114	WO 01/45748	June 28, 2001	PCT					
	B115	WO 01/46408	June 28, 2001	PCT					
	B116	WO 01/47955	July 5, 2001	PCT					
	B117	WO 01/54701	August 2, 2001	PCT					
	B118	WO 01/54719	August 2, 2001	PCT					
	B119	WO 01/60838	August 23, 2001	PCT					
	B120	WO 01/60393	August 23, 2001	PCT					
	B121	EP 0187041	July 9, 1986	EPO					

Examiner: 

Date Considered: 03/21/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 11 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1625 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

NC	B122	EP 0199301A1	October 29, 1986	EPO				
	B123	EP 0242216	October 21, 1987	EPO				
	B124	EP 0314317A1	May 3, 1989	EPO				
	B125	EP 0449116B1	October 2, 1991	EPO				
	B126	EP 0617132A2	September 28, 1994	EPO				
	B127	0 449 116 A1	October 2, 1991	EPO				
	B128	EP 0449116B1	August 11, 1999	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Ex'r Initial	Ref. No.	Description
NC	C1	GenBank accession no: AF110965
	C2	GenBank accession no: AF110967
	C3	GenBank accession no: AF110968
	C4	GenBank accession no: AF110975
	C5	GenBank accession no: M65024
	C6	Adams et al., "The Expression of Hybrid HIVty Virus-lik Particles In Yeast," <i>Nature</i> 329:68-70 (1987)

Examiner:

Date Considered:

03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 12 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1635 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C7	Anderson, et al., "Human Gene Therapy," <i>Nature</i> <u>392</u> (6679 Suppl):25-30 (1998)
	C8	Andre et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp 120 Sequence with Optimized Condon Usage," <i>Journal of Virology</i> <u>72</u> (2):1497-1503 (1998);
	C9	Arthur, et al., "Serological Responses in Chimpanzees Inoculated with Human Immunodeficiency Virus Glycoprotein (Gp120) Subunit Vaccine," <i>Proc Natl Acad Sci USA</i> <u>84</u> (23):8583-8587 (1987)
	C10	Azevedo et al., "Main Features of DNA-Based Immunization Vectors," <i>Braz J Med Biol Res.</i> <u>32</u> (2):147-153 (1999)
	C11	Baker et al., "Structures of Bovine and Human Papillomaviruses. Analysis by Cryoelectron Microscopy and Three-dimensional Image Reconstruction," <i>Biophys. J.</i> <u>60</u> :1445-1456 (1991)
	C12	Barr, et al., "Antigenicity and Immunogenicity of Domains of the Human Immunodeficiency Virus (HIV) Envelope Polypeptide Expressed in the Yeast <i>Saccharomyces cerevisiae</i> ," <i>Vaccine</i> <u>5</u> (2):90-101 (1987)
	C13	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," <i>Science</i> <u>220</u> :868-871 (1983);
	C14	Barrett, et al., "Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity," <i>AIDS Res Hum Retroviruses</i> <u>5</u> (2):159-71 (1989)
	C15	Beard, W. A., et al., "Role of the 'Helix Clamp' in HIV-1 Reverse Transcriptase Catalytic Cycling as Revealed by Alanine-Scanning Mutagenesis," <i>Journal Of Biological Chemistry</i> <u>271</u> (21):12213-12220 (1996)
	C16	Berger, P.B., "New Directions in Research: Report from the 10th International Conference on AIDS," <i>Canadian Medical Association Journal</i> <u>152</u> (12):1991-1995 (1995)
	C17	Berman, et al., "Human Immunodeficiency Virus Type 1 Challenge of Chimpanzees Immunized with Recombinant Envelope Glycoprotein gp120," <i>Proc Natl Acad Sci USA</i> <u>85</u> (14):5200-5204 (1988)
↓	C18	Berman, et al., "Expression and Immunogenicity of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, gp160," <i>J Virol.</i> <u>63</u> (8):3489-3498 (1989)

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial If citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3TD11.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 13 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1635 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C19	Birx and Redfield, "HIV Vaccine Therapy," <i>Int J Immunopharmacol.</i> <u>13</u> (1):129-132 (1991)
	C20	Bolognesi, D.P., "Progress in Vaccines Against AIDS," <i>Science</i> <u>246</u> :1233-1234 (1989)
	C21	Borrow, et al., "Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection," <i>J Virol.</i> <u>68</u> (9):6103-6110 (1994)
	C22	Bourgault, et al., "Cytotoxic T-Cell Response and AIDS-Free Survival in Simian Immunodeficiency Virus-Infected Macaques," <i>AIDS</i> , <u>7</u> (Suppl 2):S73-S79 (1993)
	C23	Brown et al., "Chimeric Parvovirus B19 Capsids for the Presentation of Foreign Epitopes," <i>Virology</i> <u>198</u> :477-488 (1994)
	C24	Bujacz, G., et al., "The Catalytic Domain of Human Immunodeficiency Virus Integrase: Ordered Active Site in the F185H Mutant," <i>Febs Letters</i> , <u>398</u> (2-3):175-178 (1996)
	C25	Burton et al., "Why Do We Not Have an HIV Vaccine and How Can We Make One?" <i>Nat Med.</i> <u>4</u> (5 Suppl):495-498 (1998)
	C26	Carmichael et al., "Quantitative Analysis of the Human Immunodeficiency Virus Type 1 (Hiv-1)-specific Cytotoxic T Lymphocyte (Ct) Response at Different Stages of Hiv-1 Infection: Differential Ct Responses to Hiv-1 and Epstein-barr Virus in Late Disease," <i>J Exp Med.</i> <u>177</u> (2):249-256 (1993)
	C27	Chazal N. et al., "Phenotypic Characterization of Insertion Mutants of the Human Immunodeficiency Virus Type 1 Gag Precursor Expressed in Recombinant Baculovirus-Infected Cells," <i>Virology</i> <u>68</u> (1):111-122 (1994)
	C28	Chu et al., <i>J. Mol. Med.</i> , "Retrovirus-mediated gene transfer into human hematopoietic stem cells," 1998, 76:pp. 184-192
	C29	Ciernik et al., "Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with Dna Vaccines Expressing Single T Cell Epitopes," <i>J. Immunol.</i> <u>156</u> (7):2369-2375 (1996)
	C30	Clavel et al., "Isolation of a New Human Retrovirus from West African Patients with AIDS," <i>Science</i> <u>233</u> :343-346 (1986)
	C31	Clavel et al., "Molecular Cloning and Polymorphism of the Human Immune Deficiency Virus Type 2," <i>Nature</i> <u>324</u> :691-695 (1986)

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 14 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1633 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
WC	C32	Daar et al., "Transient High Levels of Viremia in Patients with Primary Human Immunodeficiency Virus Type 1 Infection," <i>N Engl J Med.</i> 324(14):961-964 (1991)
	C33	Davey et al., "Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons," <i>J Infect Dis.</i> 175(4):781-789 (1997)
	C34	Davies J. F., et al., "Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase," <i>Science</i> 252(5002):88-95 (1991)
	C35	Deminle et al., "Evaluation of Reverse Transcriptase and Protease Inhibitors in Two-drug Combinations Against Human Immunodeficiency Virus Replication," <i>Antimicrob Agents Chemother.</i> 40(6):1346-1351 (1996)
	C36	Desai et al., "Molecular Cloning and Primary Nucleotide Sequence Analysis of a Distinct Human Immunodeficiency Virus Isolate Reveal Significant Divergence in its Genomic Sequence," <i>Proc. Natl. Acad. Sci. USA</i> 83:8380-8384 (1986)
	C37	Doe et al., "Induction of HIV-1 Envelope (gp120)-Specific Cytotoxic T Lymphocyte Responses in Mice by Recombinant CHO Cell-Derived gp120 is Enhanced by Enzymatic Removal of N-Linked Glycans," <i>Eur. J. Immunol.</i> 24:2369-2376 (1994)
	C38	Doe, B. and Walker, C.M. "HIV-1 p24 Gag-Specific Cytotoxic T-Lymphocyte Responses in Mice," <i>AIDS</i> 10(7):793-794 (1996)
	C39	Dyda F., et al., "Crystal Structure of the Catalytic Domain of HIV-1 Integrase: Similarity to Other Polynucleotidyl Transferases," <i>Science</i> 266(5193):1981-1986 (1994)
	C40	Earl et al., "Isolate-and Group-specific Immune Responses to the Envelope Protein of Human Immunodeficiency Virus Induced by a Live Recombinant Vaccinia Virus in Macaques," <i>AIDS Res Hum Retroviruses</i> 5(1):23-32 (1989)
	C41	Edelman, R., "Vaccine Adjuvants," <i>Rev Infect Dis.</i> 2(3):370-383 (1980)
	C42	Engelman, A. et al., "Structure-based Mutagenesis of the Catalytic Domain of Human Immunodeficiency Virus Type 1 Integrase," <i>Journal Of Virology</i> 71(5):3507-3514 (1997)
	C43	Esnouf et al., "Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors," <i>Structural Biology</i> 2(4):303-308 (1995)

Examiner:

Date Considered:

03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

- NC - References were not considered



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 15 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2906

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1635 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C44	Evans et al., "An Engineered Poliovirus Chimaera Elicits Broadly Reactive Hiv-1 Neutralizing Antibodies," <i>Nature</i> <u>339</u> (6223):385-388 (1989)
	C45	Faust et al., "Outpatient Biopsies of the Palatine Tonsil: Access to Lymphoid Tissue for Assessment of Human Immunodeficiency Virus RNA Titers," <i>Otolaryngol Head Neck Surg.</i> <u>114</u> (4):593-598 (1996)
	C46	Fennie et al., "Model for Intracellular Folding of the Human Immunodeficiency Virus Type 1 gp120," <i>J Virol.</i> <u>63</u> (2):639-646 (1989)
	C47	Ferre et al., "Combination Therapies Against HIV-1 Infection: Exploring the Concept of Combining Antiretroviral Drug Treatments with HIV-1 Immune-Based Therapies in Asymptomatic Individuals," <i>AIDS Patient Care STDS</i> <u>10</u> (6):357-361 (1996)
	C48	Fisher, et al., "Biologically diverse molecular variants within a single HIV-1 isolate," <i>Nature</i> <u>334</u> :444-447 (1988)
	C49	Freed, E.O., "HIV-1 Gag Proteins: Diverse Functions in the Virus Life Cycle," <i>Virology</i> <u>251</u> :1-15 (1998)
	C50	Fox et al., "No Winners Against AIDS," <i>BioTechnology</i> <u>12</u> (2):128 (1994)
	C51	Garnier, L. et al., "Particle Size Determinants in the Human Immunodeficiency Virus Type 1 Gag Protein," <i>J Virol</i> <u>72</u> (6):4667-4677 (1998)
	C52	Goldgur, Y. et al., "Three New Structures of the Core Domain of HIV-1 Integrase: an Active Site That Binds Magnesium," <i>Proceedings Of the National Academy Of Sciences Of the United States Of America</i> <u>95</u> (16):9150-9154 (1998)
	C53	Goudsmit et al., "Human Immunodeficiency Virus Type 1 Neutralization Epitope with Conserved Architecture Elicits Early Type-specific Antibodies in Experimentally Infected Chimpanzees," <i>Proc. Natl. Acad. Sci. USA</i> <u>85</u> :4478-4482 (1988)
	C54	Greene, "AIDS and the Immune System," <i>Scientific American</i> Sep.:99-105 (1993)
	C55	Griffiths J.C. et al., "Hybrid Human Immunodeficiency Virus Gag Particles as an Antigen Carrier System: Induction of Cytotoxic T-cell and Humoral Responses by a Gag:V3 Fusion," <i>J. Virol.</i> <u>67</u> (6):3191-3198 (1993)

Examiner: [Signature]

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 16 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/1300

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 163 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C56	Grimison B. and Laurence, J., "Immunodominant Epitope Regions of HIV-1 Reverse Transcriptase: Correlations with HIV-1+ Serum IgG Inhibitory to Polymerase Activity and With Disease Progression," <i>Journal Of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> 9(1):58-68 (1995)
	C57	Gurgo et al., "Envelope Sequences of Two New United States HIV-1 Isolates," <i>Virology</i> 164:531-536 (1988)
	C58	Gurunathan et al., "CD40 Ligand/Trimer DNA Enhances Both Humoral and Cellular Immune Responses and Induces Protective Immunity to Infectious and Tumor Challenge," <i>J Immunol.</i> 161(9):4563-4571 (1998)
	C59	Guyader et al., "Genome Organization and Transactivation of the Human Immunodeficiency Virus Type 2," <i>Nature</i> 326:662-669 (1987)
	C60	Haas et al., "Codon Usage Limitation in the Expression of HIV-1 Envelope Glycoprotein," <i>Current Biology</i> 6(3):315-324 (1996)
	C61	Hagensee et al., "Three-dimensional Structure of Vaccinia Virus-produced Human Papillomavirus Type 1 Capsids," <i>J. Virol.</i> 68:4503-4505 (1994)
	C62	Hahn et al., "Genetic Variation in HTLV-III/LAV Over Time in Patients with AIDS or at Risk for AIDS," <i>Science</i> 232:1548-1553 (1986)
	C63	Halene et al., Human Gene Therapy, "Gene Therapy Using Hematopoietic Stem Cells: Sisyphus Approaches the Crest," June 2000, 11:1259-1267
	C64	Hammer et al., "Issues in Combination Antiretroviral Therapy: a Review," <i>J Acquir Immune Defic Syndr.</i> 7(Suppl 2):S24-S37 (1994)
	C65	Haynes et al., "Update on the Issues of Hiv Vaccine Development," <i>Ann Med.</i> 28(1):39-41 (1996)
	C66	Haynes et al., "Toward an Understanding of the Correlates of Protective Immunity to Hiv Infection" <i>Science</i> 271:324-328 (1996)
	C67	Heeney et al., "Beta-chemokines and Neutralizing Antibody Titers Correlate with Sterilizing Immunity Generated in HIV-1 Vaccinated Macaques," <i>Proc Natl Acad Sci USA</i> 95(18):10803-10808 (1998)

Examiner:

Date Considered: 03/31/00

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 17 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~1638~~ 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
<i>NC</i>	C68	Hickman, A. B., et al., "Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase," <i>Journal Of Biological Chemistry</i> 269(46):29279-29287 (1994)
	C69	Ho et al., "Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins," <i>J Virol.</i> 61(6):2024-2028 (1987)
	C70	Jacobo-Molina, A. et al., "Crystal Structure of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Complexed with Double-stranded DNA at 3.0 A Resolution Shows Bent DNA," <i>Proceedings Of the National Academy Of Sciences Of the United States Of America</i> 90(13):6320-6324 (1993)
	C71	Katz, R. A. and Skalka, A. M., "The Retroviral Enzymes," <i>Annual Review Of Biochemistry</i> 63:133-73 (1994)
	C72	Keefer, et al., "Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group," <i>AIDS Res Hum Retroviruses.</i> 12(8):683-693 (1996)
	C73	Kimbauer et al., "Efficient Self-assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles," <i>J. Virol.</i> 67:6929-6936 (1993)
	C74	Klennerman, et al., "Original Antigenic Sin Impairs Cytotoxic T Lymphocyte Responses to Viruses Bearing Variant Epitopes," <i>Nature</i> 394(6692):482-485 (1998)
	C75	Koff et al., "Development and Testing of AIDS Vaccines," <i>Science</i> 241:426-432 (1988)
	C76	Koff and Schultz, "Progress and Challenges Toward and AIDS Vaccine: Brother, Can You Spare a Paradigm?" <i>J. Clinical Immunology</i> 16(3):127-133 (1996)
	C77	Kohl et al., "Active Human Immunodeficiency Virus Protease Is Required for Viral Infectivity," <i>PNAS USA</i> 85:4686-4690 (1988)
	C78	Kohlstaedt, L. A. et al., "Crystal Structure at 3.5 A Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor," <i>Science</i> 256(5065):1783-1790 (1992)
	C79	Koup et al., "Temporal Association of Cellular Immune Responses with the Initial Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Syndrome," <i>J Virol.</i> 68(7):4650-4655 (1994)
	C80	Kovacs et al., "Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection," <i>New England J. Med.</i> 332(9):567-575 (1995)

Examiner: *[Signature]*

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 18 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C81	Kovacs et al., "Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus," <i>N Engl J Med.</i> <u>335</u> (18):1350-1356 (1996)
	C82	Krausslich et al., "Processing of in Vitro-synthesized Gag Precursor Proteins of Human Immunodeficiency Virus (HIV) Type 1 by HIV Proteinase Generated in <i>Escherichia coli</i> ," <i>J. Virol.</i> <u>62</u> :4393-4397 (1988)
	C83	Kreuter J., et al., "Mode of Action of Immunological Adjuvants: Some Physicochemical Factors Influencing the Effectivity of Polyacrylic Adjuvants," <i>Infect Immun.</i> <u>19</u> (2):667-675 (1978)
	C84	Krug, M. S. and Berger, S. L., "Reverse Transcriptase from Human Immunodeficiency Virus: a Single Template-primer Binding Site Serves Two Physically Separable Catalytic Functions," <i>Biochemistry</i> <u>30</u> (44):10614-10623 (1991)
	C85	Kuby, Immunology, "Vaccines," 2 nd Ed., WH Freeman and Company 1994, pp. 469-471
	C86	Lalvani A. et al., "Rapid effector Function in CD8+ Memory T Cells," <i>J. Exp. Med.</i> <u>186</u> :859-865 (1997)
	C87	Lasky et al., "Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 Receptor," <i>Cell</i> <u>50</u> (6):975-985 (1987)
	C88	Levy et al., "Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS," <i>Science</i> <u>225</u> :840-842 (1984)
	C89	Littman et al., "Unusual Intron in the Immunoglobulin Domain of the Newly Isolated Murine CD4 (L3T4) Gene," <i>Nature</i> <u>325</u> (6103):453-455 (1987)
	C90	Looney et al., "Type-restricted Neutralization of Molecular Clones of Human Immunodeficiency Virus," <i>Science</i> <u>241</u> :357-359 (1988)
	C91	Maddon et al., "The Isolation and Nucleotide Sequence of a Cdna Encoding the T Cell Surface Protein T4: a New Member of the Immunoglobulin Gene Family," <i>Cell</i> <u>42</u> (1):93-104 (1985)
	C92	Maignan, S., et al. "Crystal Structures of the Catalytic Domain of HIV-1 Integrase Free and Complexed with its Metal Cofactor: High Level of Similarity of the Active Site with Other Viral Integrases," <i>Journal Of Molecular Biology</i> <u>282</u> (2):359-368 (1998)

Examiner:

Date Considered:

03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 19 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1800/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~1835~~ 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C93	Manca et al., "Antigenicity of HIV-derived T Helper Determinants in the Context of Carrier Recombinant Proteins: Effect on T Helper Cell Repertoire Selection," <i>Eur J Immunol.</i> 26(10):2461-2469 (1996)
	C94	Mazumder, A., et al., "Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase," <i>Molecular Pharmacology</i> 49(4):621-628 (1996)
	C95	Mazza et al., "Recombinant Interleukin-2 (Ril-2) in Acquired Immune Deficiency Syndrome (Aids): Preliminary Report in Patients with Lymphoma Associated with HIV Infection," <i>Eur J Haematol.</i> 49(1):1-6 (1992)
	C96	McHeyzer-Williams, M.G. et al, "Enumeration and Characterization of Memory Cells in the Th Compartment," <i>Immunol. Rev.</i> 150:5-21 (1996)
	C97	McCluskie, et al., "Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates," <i>Mol Med.</i> 5(5):287-300 (1999)
	C98	McComack et al., "HIV Protease Substrate Conformation: Modulation by Cyclophilin A," <i>FEBS Letts</i> 414:84-88 (1997)
	C99	McMichael, A.J. and O'Callaghan, C.A., "A New Look at T Cells," <i>J. Exp. Med.</i> 187(9):1367-1371 (1998)
	C100	Modrow et al., "Computer-assisted Analysis of Envelope Protein Sequences of Seven Human Immunodeficiency Virus Isolates: Prediction of Antigenic Epitopes in Conserved and Variable Regions," <i>J. Virol.</i> 61(2):570-578 (1987)
	C101	Montagnier et al., "Human T-Cell Leukemia Viruses: The Family of Human T-Lymphotropic Retroviruses: Their Role in Malignancies and Association with AIDS," <i>Gallo, Essex & Gross, eds.</i> , pp 363-379 (1984)
	C102	Myers et al., "Human Retroviruses and AIDS," published by the Los Alamos National Laboratory, Los Alamos, NM, 1991, pp. I-A-48 to I-A-56 and II-77 to II-88
	C103	Nathanson et al., "Biological Considerations in the Development of a Human Immunodeficiency Virus Vaccine," <i>J Infect Dis.</i> 182(2):579-589 (2000)
	C104	Novitsky et al., "Molecular Cloning and Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Subtype C: a Set of 23 Full-Length Clones from Botswana," <i>J. Virol.</i> 73(5):4427-4432 (1999)
	C105	Nowak and Bangham, "Population Dynamics of Immune Responses to Persistent Viruses," <i>Science</i> 272(5258):74-79 (1996)


Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 20 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~1953~~ 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
WC	C106	Odile et al., "Anti-HIV Active Immunization, Evidence for Persistent Cell Mediated Immunity after a 2 Year Follow Up," Eighth International Conference on AIDS/III STD World Congress Amsterdam, The Netherlands 19-24 July 1992, Abstract No. MOB 0024
	C107	Okuda et al., "Induction of Potent Humoral and Cell-mediated Immune Responses Following Direct Injection of DNA Encoding the HIV Type 1 Env and Rev gene Products," <i>AIDS Res Hum Retroviruses</i> 11(8):933-943 (1995)
	C108	Palaniappan, C. et al., "Mutations Within the Primer Grip Region of HIV-1 Reverse Transcriptase Result in Loss of RNase H Function," <i>Journal Of Biological Chemistry</i> 272(17):11157-11164 (1997)
	C109	Park et al., "Overexpression of The Gag-pol Precursor From Human Immunodeficiency Virus Type 1 Proviral Genomes Results in Efficient Proteolytic Processing in The Absence of Virion Production," <i>J. Virol.</i> 65:5111 (1991)
	C110	Patel et al., "Insights Into DNA Polymerization Mechanisms from Structure and Function Analysis of HIV-1 Reverse Transcriptase," <i>Biochemistry</i> 34:5351-5363 (1995)
	C111	Perelson, et al., "Decay Characteristics of Hiv-1-Infected Compartments During Combination Therapy," <i>Nature</i> 382(6629):188-191 (1997)
	C112	Popovic et al., "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS," <i>Science</i> 224:497-500 (1984)
	C113	Pyle et al., "Immune Response to Immunostimulatory Complexes (ISCOMs) Prepared from Human Immunodeficiency Virus Type 1 (HIV-1) or the HIV-1 External Envelope Glycoprotein (gp120)," <i>Vaccine</i> 7(5):465-473 (1989)
	C114	Redfield and Blix, "Hiv-specific Vaccine Therapy: Concepts, Status, and Future Directions," <i>AIDS Res Hum Retroviruses</i> 8(6):1051-1058 (1992)
	C115	Reicin, A.S. et al., "Linker Insertion Mutations in the Human Immunodeficiency Virus Type 1 Gag Gene: Effects on Virion Particle Assembly, Release, and Infectivity," <i>J. Virol.</i> 69(2):642-650 (1995)
	C116	Richter et al., International Journal of Hematology, "Clinical Gene Therapy in Hematology: Past and Future," 2000, pp. 162-169

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T01LDOC

WC - references were not considered.



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 21 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: 1653 / 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C117	Robey, et al., "Prospect for Prevention of Human Immunodeficiency Virus Infection: Purified 120-kDa Envelope Glycoprotein Induces Neutralizing Antibody," <i>Proc Natl Acad Sci USA</i> <u>83</u> (18):7023-7027 (1986)
	C118	Rodgers, D. W. et al., "The Structure of Unliganded Reverse Transcriptase from the Human Immunodeficiency Virus Type 1," <i>Proceedings Of the National Academy Of Sciences Of the United States Of America</i> <u>92</u> (4):1222-1226 (1995)
	C119	Romano et al., Stem Cells, "Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications," 2000, 18:19-39
	C120	Saag, et al., "Extensive Variation of Human Immunodeficiency Virus Type-1 <i>in vivo</i> ," <i>Nature</i> <u>334</u> :440-444 (1988)
	C121	Saag and Kuritzkes, "Strategies for Continuing Antiretroviral Therapy," <i>Intl AIDS Society USA</i> <u>4</u> (2):16-19 (1996)
	C122	Salk et al., "Prospects for the Control of Aids by Immunizing Seropositive Individuals," <i>Nature</i> <u>327</u> (6122):473-476 (1987)
	C123	Schemthaner, et al., "Endosperm-specific Activity of a Zein Gene Promoter in Transgenic Tobacco Plants," <i>The EMBO J.</i> <u>7</u> :1249-1259 (1988)
	C124	Schneider et al., "Inactivation of the Human Immunodeficiency Virus Type 1 Inhibitory Elements Allows Rev-Independent Expression of Gag and Gag/Protease and Particle Formation," <i>Journal of Virology</i> <u>71</u> (7):4892-4903 (1997)
	C125	Schulhafer et al., "Acquired Immunodeficiency Syndrome: Molecular Biology and its Therapeutic Intervention (review)," <i>In Vivo</i> <u>3</u> (2):61-78 (1989)
	C126	Sheng N. and Dennis, D., "Active Site Labeling of HIV-1 Reverse Transcriptase," <i>Biochemistry</i> <u>32</u> (18):4938-4942 (1993)
	C127	Smith et al., "Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen," <i>Science</i> <u>238</u> (4834):1704-1707 (1987)
↓	C128	Spence R. A., et al., "Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors," <i>Science</i> <u>267</u> (5200):988-993 (1995)

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial If citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
648137 v1/PA
DW3T011.DOC

NC-References were not considered.



COMMISSIONER OF PATENTS AND TRADEMARK
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 22 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Serial No.: 09/899,575

Filed: July 5, 2001

Examiner: Unassigned

Art Unit: 1625 **1648**

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C129	Srinivasan et al., "Molecular Characterization of Human Immunodeficiency Virus from Zaire: Nucleotide Sequence Analysis Identifies Conserved and Variable Domains in the Envelope Gene," <i>Gene</i> 52 :71-82 (1987)
	C130	Starich et al., "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS," <i>Cell</i> 45 :637-648 (1986)
	C131	Stedman's Medical Dictionary, Williams & Wilkins, 26 th Ed., 1995, pp. 852-853
	C132	Steimer et al., "Genetically Engineered Human Immunodeficiency Envelope Glycoprotein Gp120 Produced in Yeast Is the Target of Neutralizing Antibodies," <i>Vaccines</i> 87 :236-241 (1987)
	C133	Sternberg et al., "Prediction of Antigenic Determinants and Secondary Structures of the Major Aids Virus Proteins," <i>FEBS Letters</i> 218 (2):231-237 (1987)
	C134	Tindle et al., "Chimeric Hepatitis B Core Antigen Particles Containing B- and Th-epitopes of Human Papillomavirus Type 16 E7 Protein Induce Specific Antibody and T-helper Responses in Immunised Mice," <i>Virology</i> 200 :547-557 (1994)
	C135	Vacca et al., "L-735,524: an Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor," <i>Proc Natl Acad Sci USA</i> 91 (9):4096-4100 (1994)
	C136	Verma et al., "Gene therapy -- Promises, Problems and Prospects," <i>Nature</i> 389 (6648):239-242 (1997)
	C137	VFI Van Tendeloo et al., Leukemia, "Gene therapy: principles and applications to hematopoietic cells," 2001, 15: pp. 523-544
	C138	Vilmer et al., "Isolation of New Lymphotropic Retrovirus from Two Siblings with <i>Haemophilia B</i> , One with AIDS," <i>The Lancet</i> 1 :753 (1984)
	C139	Wagner R., et al., "Studies on Processing, Particle Formation, and Immunogenicity of the HIV-1 gag Gene Product: a Possible Component of a HIV Vaccine," <i>Arch Virol.</i> 127 :117-137 (1992)
	C140	Wagner et al., "Assembly and Extracellular Release of Chimeric HIV-1 PR55gag Retrovirus-like Particles," <i>Virology</i> 200 :162-175 (1994)
	C141	Wagner et al., "Construction, Expression, and Immunogenicity of Chimeric HIV-1 Virus-like Particles," <i>Virology</i> 220 :128-140 (1996)

Examiner:

Date Considered: 03/31/04

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - References were not considered



COMMISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 23 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Serial No.: 09/899,575

Filed: July 5, 2001

Examiner: Unassigned

Art Unit: ~~1853~~ 1648

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C142	Wakefield, J. K. et al., "In Vitro Enzymatic Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants in the Highly Conserved YMDD Amino Acid Motif Correlates with the Infectious Potential of the Proviral Genome," <i>Journal Of Virology</i> 66(11):6806-6812 (1992)
	C143	Wan et al., "Autoprocessing: an Essential Step for the Activation of HIV-1 Protease," <i>Biochem. J.</i> 316:569-573 (1996)
	C144	Wang et al., "Assembly of HIV GAG-B-Galactosidase Fusion Proteins Into Virus Particles," <i>Virology</i> 200:524-534 (1994)
	C145	Wang et al., "Induction of Humoral and Cellular Immune Responses to the Human Immuno-deficiency Type 1 Virus in Nonhuman Primates by in Vivo DNA Inoculation," <i>Virology</i> 211(1):102-112 (1995)
	C146	Wang C. et al., "Analysis of Minimal Human Immunodeficiency Virus Type 1 Gag Coding Sequences Capable of Virus-like Particle Assembly and Release," <i>J Virol</i> 72(10): 7950-7959 (1998)
	C147	Wu X., et al., "Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx," <i>J. Virol.</i> 69(6):3389-3398 (1995)
	C148	Yeni et al., "Antiretroviral and Immune-based Therapies: Update," <i>AIDS</i> 7(Suppl 1):S173-S184 (1993)
	C149	Yenofsky et al., "A Mutant Neomycin Phosphotransferase II Gene Reduces the Resistance of Transformants to Antibiotic Selection Pressure," <i>Proc. Natl. Acad. Sci. USA</i> 87:3435-3439 (1990)
	C150	Yourno et al., "Nucleotide Sequence Analysis of the Env Gene of a New Zairian Isolate of HIV-1," <i>AIDS Res Hum Retroviruses</i> 4(3):165-73 (1988)
	C151	Zagury et al., "Progress Report IV on Aids Vaccine in Human: Phase I Clinical Trial in Hiv Infected Patients," <i>VII International Conference on AIDS, Florence June 16-21, 1991, Abstract No. M.A. 67</i>
	C152	Zagury et al., "One-year Follow-up of Vaccine Therapy In Hiv-Infected Immune-deficient Individuals: a New Strategy," <i>J. Acquired Immune Deficiency Syndromes</i> 5:676-681 (1992)
↓	C153	Zhang Y., et al., "Analysis of the Assembly Function of the Human Immunodeficiency Virus Type 1 Gag Protein Nucleocapsid Domain," <i>J Virol</i> 72(3):1782-1789 (1998)

Examiner:

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T01.DOC

NC - References were not considered.



C ISSIONER OF PATENTS AND TRADEMAR
P.O. Box 1450
Alexandria, VA 22313-1450

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
Sheet 24 of 24

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

In re the Application of Barnett et al.

Examiner: Unassigned

Serial No.: 09/899,575

Art Unit: ~~1633~~ 1648

Filed: July 5, 2001

Confirmation No.: 1709

Title: POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

Atty. Docket No.: PP01631.102 (CHIR-1631/03US)

Ex'r Initial	Ref. No.	Description
NC	C154	zur Megede et al., "Increased Expression and Immunogenicity of Sequence-modified Human Immunodeficiency Virus Type 1 Gag Gene," <i>J Virol.</i> 74(6):2628-2635 (2000)

Examiner: 

Date Considered: 03/31/06

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

648137 v1/PA
DW3T011.DOC

NC - Reference was not considered.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/899,575		
		Filing Date	July 5, 2001		
		First Named Inventor	ZUR MEGEDE et al.		
		Group Art Unit	1648		
Sheet	1	of	1	Examiner Name	B. Whitman PARKER, JEFFREY
				Attorney Docket Number	PP001631.0102 (2300-1631.21)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
J	B1	WO	97/31115		Merck & Co., Inc.	08-28-1997	
	B2	WO	99/41397		Oxford Biomedica Limited	08-19-1999	
	B3	WO	00/15819		The Children's Medical Center	03-23-2000	
	B4	WO	03/004620	A2	Chiron Corporation	01-16-2003	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
J	C1	Haas et al., "CYTOTOXIN T-CELL RESPONSES TO HIV-1 REVERSE TRANSCRIPTASE, INTEGRASE AND PROTEASE," AIDS, 12:1427-1436 (1998).			
	C2	Hamajima, et al., "THE COMBINATION OF DNA AND PEPTIDE VACCINES INDUCES STRONG IMMUNITIES AGAINST HIV-1 IN BOTH HUMORAL AND CMI," 11 TH International AIDS Conference, Vancouver, British Columbia, July 7-12; 11:6 (abstract no. Mo.A.151) (1996).			
	C3	Kent, et al., "A RECOMBINANT AVIPOXVIRUS HIV-1 VACCINE EXPRESSING INTERFERON-GAMMA IS SAFE AND IMMUNOGENIC IN MACAQUES," Vaccine 18:2250-2256 (2000).			
	C4	Williamson, et al., "DESIGNING HIV-1 SUBTYPE C VACCINES FOR SOUTH AFRICA," South African Journal of Science, 96:318-324 (2000).			

Examiner Signature		Date Considered	03/31/06
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.